In vitro and in vivo evaluation of combined calcitriol and cisplatin in dogs with spontaneously occurring tumors

Cancer Chemotherapy and Pharmacology

Volumn 62, Issue 5, 2008, Pages 881-891

  Rassnick, Kenneth M ^a   Muindi, Josephia R ^b   Johnson, Candace S ^b   Balkman, Cheryl E ^a   Ramnath, Nithya ^b   Yu, Wei Dong ^b   Engler, Kristie L ^b   Page, Rodney L ^a   Trump, Donald L ^b  

^a Animal Health Diagnostic Center   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

1,25 Dihydroxyvitamin D3; Cancer; Canine; Pharmacokinetics; Platinum; Vitamin D

Indexed keywords

CALCITRIOL; CISPLATIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CYTOTOXICITY; DIARRHEA; DOG; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG DOSE ESCALATION; DRUG POTENTIATION; DRUG SAFETY; FEMALE; HYPERCALCEMIA; HYPERSENSITIVITY REACTION; IN VITRO STUDY; IN VIVO STUDY; MALE; MASTOCYTOMA; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MELANOMA; NEUTROPENIA; NONHUMAN; OSTEOSARCOMA CELL; PRIORITY JOURNAL; TUMOR CELL; VOMITING;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; CALCITRIOL; CELL LINE, TUMOR; CISPLATIN; DOG DISEASES; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG HYPERSENSITIVITY; GASTROINTESTINAL DISEASES; HEMATOLOGIC DISEASES; INJECTIONS, INTRAVENOUS; NEOPLASMS; TETRAZOLIUM SALTS; THIAZOLES; VITAMINS;

EID: 49749146435     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-008-0678-x     Document Type: Article

References (61)

1. (2004) Veterinary co-operative oncology group common terminology criteria for adverse events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.0. Vet Compar Oncol 2:195-213
2. MJ Beckman P Tadikonda E Werner J Prahl S Yamada HF DeLuca 1996 Human 25-hydroxyvitamin D3-24-hydroxylase, a multicatalytic enzyme Biochemistry 35 8465 8472
3. TM Beer MM Javle CW Ryan M Garzotto GN Lam A Wong WD Henner CS Johnson DL Trump 2007 Phase I study of weekly DN-101, a new formulation of calcitriol, in patients with cancer Cancer Chemother Pharmacol 59 581 587
4. TM Beer M Munar WD Henner 2001 A phase I trial of pulse calcitriol in patients with refractory malignancies: pulse dosing permits substantial dose escalation Cancer 91 2431 2439
5. RJ Bernardi DL Trump WD Yu TF McGuire PA Hershberger CS Johnson 2001 Combination of 1alpha,25-dihydroxyvitamin D(3) with dexamethasone enhances cell cycle arrest and apoptosis: role of nuclear receptor cross-talk and Erk/Akt signaling Clin Cancer Res 7 4164 4173
6. BJ Boyle XY Zhao P Cohen D Feldman 2001 Insulin-like growth factor binding protein-3 mediates 1 alpha,25-dihydroxyvitamin d(3) growth inhibition in the LNCaP prostate cancer cell line through p21/WAF1 J Urol 165 1319 1324
7. Brown SA, Finco DR (1995) Reassessment of the use of calcitriol in chronic renal failure. In: Bonagura JD (ed) Kirk's current veterinary therapy XII small animal practice. W.B. Saunders Co, Philadelphia, pp 963-966
8. MJ Campbell HP Koeffler 1997 Toward therapeutic intervention of cancer by vitamin D compounds J Natl Cancer Inst 89 182 185
9. N Chattopadhyay RJ MacLeod J Tfelt-Hansen EM Brown 2003 1alpha,25(OH)2-vitamin D3 inhibits HGF synthesis and secretion from MG-63 human osteosarcoma cells Am J Physiol Endocrinol Metab 284 E219 E227
10. YL Cho C Christensen DE Saunders WD Lawrence G Deppe VK Malviya JM Malone 1991 Combined effects of 1,25-dihydroxyvitamin D3 and platinum drugs on the growth of MCF-7 cells Cancer Res 51 2848 2853
11. R Chun DW Knapp WR Widmer NW Glickman DB DeNicola PL Bonney 1996 Cisplatin treatment of transitional cell carcinoma of the urinary bladder in dogs: 18 cases (1983-1993) J Am Vet Med Assoc 209 1588 1591
12. I Chung WD Yu AR Karpf G Flynn RJ Bernardi RA Modzelewski CS Johnson DL Trump 2007 Anti-proliferative effects of calcitriol on endothelial cells derived from two different microenvironments J Steroid Biochem Mol Biol 103 768 770
13. JC Deak JV Cross M Lewis Y Qian LA Parrott CW Distelhorst DJ Templeton 1998 Fas-induced proteolytic activation and intracellular redistribution of the stress-signaling kinase MEKK1 Proc Natl Acad Sci USA 95 5595 5600
14. R DeVinney WM Gold 1990 Establishment of two dog mastocytoma cell lines in continuous culture Am J Respir Cell Mol Biol 3 413 420
15. E Elstner D Heber HP Koeffler 1996 20-Epi-vitamin D3 analogs. Potent modulators of proliferation and differentiation of breast cancer cell lines in vitro Adv Exp Med Biol 399 53 70
16. MG Fakih DL Trump JR Muindi JD Black RJ Bernardi PJ Creaven J Schwartz MG Brattain A Hutson R French CS Johnson 2007 A phase I pharmacokinetic and pharmacodynamic study of intravenous calcitriol in combination with oral gefitinib in patients with advanced solid tumors Clin Cancer Res 13 1216 1223
17. Feldman EC, Nelson RW (2004) Hypercalcemia and hyperparathyroidism. In: Feldman EC, Nelson RW (eds) Canine and feline endocrinology and reproduction. Saunders, St. Louis, pp 660-715
18. Feldman EC, Nelson RW (2004) Hypocalcemia and primary hypoparathyroidism. In: Feldman EC, Nelson RW (eds) Canine and feline endocrinology and reproduction. Saunders, St. Louis, pp 716-742
19. LS Fineman TA Hamilton A de Gortari P Bonney 1998 Cisplatin chemotherapy for treatment of thyroid carcinoma in dogs: 13 cases J Am Anim Hosp Assoc 34 109 112
20. DT Forman L Lorenzo 1991 Ionized calcium: its significance and clinical usefulness Ann Clin Lab Sci 21 297 304
21. G Gebauer B Mirakhur Q Nguyen SK Shore H Simpkins N Dhanasekaran 2000 Cisplatin-resistance involves the defective processing of MEKK1 in human ovarian adenocarcinoma 2008/C13 cells Int J Oncol 16 321 325
22. JG Gong A Costanzo HQ Yang G Melino WG Kaelin Jr M Levrero JY Wang 1999 The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage Nature 399 806 809
23. JD Haugen MR Pittelkow AR Zinsmeister R Kumar 1996 1 Alpha,25- dihydroxyvitamin D3 inhibits normal human keratinocyte growth by increasing transforming growth factor beta 2 release Biochem Biophys Res Commun 229 618 623
24. L Hengst SI Reed 1996 Translational control of p27Kip1 accumulation during the cell cycle Science 271 1861 1864
25. PA Hershberger TF McGuire WD Yu EG Zuhowski JH Schellens MJ Egorin DL Trump CS Johnson 2002 Cisplatin potentiates 1,25-dihydroxyvitamin D3-induced apoptosis in association with increased mitogen-activated protein kinase kinase kinase 1 (MEKK-1) expression Mol Cancer Ther 1 821 829
26. SY James AG Mackay KW Colston 1996 Effects of 1,25 dihydroxyvitamin D3 and its analogues on induction of apoptosis in breast cancer cells J Steroid Biochem Mol Biol 58 395 401
27. CS Johnson JR Muindi PA Hershberger DL Trump 2006 The antitumor efficacy of calcitriol: preclinical studies Anticancer Res 26 2543 2549
28. Johnson SW, O'Dwyer PJ (2005) Cisplatin and its analogues. In: DeVita VT, Hellman S, Rosenberg SA (eds) Cancer principles and practice of oncology. Lippincott Williams & Wilkins, Philadelphia, pp 344-358
29. T Kaewsakhorn WC Kisseberth CC Capen KA Hayes MJ Calverley N Inpanbutr 2005 Effects of calcitriol, seocalcitol, and medium-chain triglyceride on a canine transitional cell carcinoma cell line Anticancer Res 25 2689 2696
30. DW Knapp RC Richardson PL Bonney K Hahn 1988 Cisplatin therapy in 41 dogs with malignant tumors J Vet Intern Med 2 41 46
31. T Kobayashi K Hashimoto K Yoshikawa 1993 Growth inhibition of human keratinocytes by 1,25-dihydroxyvitamin D3 is linked to dephosphorylation of retinoblastoma gene product Biochem Biophys Res Commun 196 487 493
32. AV Krishnan J Moreno L Nonn P Malloy S Swami L Peng DM Peehl D Feldman 2007 Novel pathways that contribute to the anti-proliferative and chemopreventive activities of calcitriol in prostate cancer J Steroid Biochem Mol Biol 103 694 702
33. S Kunakornsawat TJ Rosol CC Capen RP Middleton SS Hannah N Inpanbutr 2001 Effects of 1,25(OH)2D3, EB1089, and analog V on PTHrP production, PTHrP mRNA expression and cell growth in SCC 2/88 Anticancer Res 21 3355 3363
34. S Kunakornsawat TJ Rosol CC Capen GS Reddy L Binderup N Inpanbutr 2002 Effects of 1,25-dihydroxyvitamin D3 [1,25(OH)2D3] and its analogues (EB1089 and analog V) on canine adenocarcinoma (CAC-8) in nude mice Biol Pharm Bull 25 642 647
35. BW Light WD Yu MC McElwain DM Russell DL Trump CS Johnson 1997 Potentiation of cisplatin antitumor activity using a vitamin D analogue in a murine squamous cell carcinoma model system Cancer Res 57 3759 3764
36. M Liu MH Lee M Cohen M Bommakanti LP Freedman 1996 Transcriptional activation of the Cdk inhibitor p21 by vitamin D3 leads to the induced differentiation of the myelomonocytic cell line U937 Genes Dev 10 142 153
37. E Masini J Planchenault F Pezziardi P Gautier JP Gagnol 1985 Histamine-releasing properties of Polysorbate 80 in vitro and in vivo: correlation with its hypotensive action in the dog Agents Actions 16 470 477
38. S Masuda V Byford A Arabian Y Sakai MB Demay R St Arnaud G Jones 2005 Altered pharmacokinetics of 1alpha,25-dihydroxyvitamin D3 and 25-hydroxyvitamin D3 in the blood and tissues of the 25-hydroxyvitamin D-24-hydroxylase (Cyp24a1) null mouse Endocrinology 146 825 834
39. KL Mealey R Barhoumi K Rogers DT Kochevar 1998 Doxorubicin induced expression of P-glycoprotein in a canine osteosarcoma cell line Cancer Lett 126 187 192
40. KA Moffatt WU Johannes GJ Miller 1999 1Alpha,25dihydroxyvitamin D3 and platinum drugs act synergistically to inhibit the growth of prostate cancer cell lines Clin Cancer Res 5 695 703
41. AS Moore A Cardona W Shapiro BR Madewell 1990 Cisplatin (cisdiamminedichloroplatinum) for treatment of transitional cell carcinoma of the urinary bladder or urethra. A retrospective study of 15 dogs J Vet Intern Med 4 148 152
42. JR Muindi RA Modzelewski Y Peng DL Trump CS Johnson 2004 Pharmacokinetics of 1alpha,25-dihydroxyvitamin D3 in normal mice after systemic exposure to effective and safe antitumor doses Oncology 66 62 66
43. JR Muindi DM Potter Y Peng CS Johnson DL Trump 2005 Pharmacokinetics of liquid calcitriol formulation in advanced solid tumor patients: comparison with caplet formulation Cancer Chemother Pharmacol 56 492 496
44. A Nehme R Baskaran S Nebel D Fink SB Howell JY Wang RD Christen 1999 Induction of JNK and c-Abl signalling by cisplatin and oxaliplatin in mismatch repair-proficient and -deficient cells Br J Cancer 79 1104 1110
45. K Okuda E Usui Y Ohyama 1995 Recent progress in enzymology and molecular biology of enzymes involved in vitamin D metabolism J Lipid Res 36 1641 1652
46. JL Omdahl HA Morris BK May 2002 Hydroxylase enzymes of the vitamin D pathway: expression, function, and regulation Annu Rev Nutr 22 139 166
47. M Pelczynska M Switalska M Maciejewska I Jaroszewicz A Kutner A Opolski 2006 Antiproliferative activity of vitamin D compounds in combination with cytostatics Anticancer Res 26 2701 2705
48. VJ Poirier AE Hershey KE Burgess B Phillips MM Turek LJ Forrest L Beaver DM Vail 2004 Efficacy and toxicity of paclitaxel (Taxol) for the treatment of canine malignant tumors J Vet Intern Med 18 219 222
49. WK Rumbeiha JM Kruger SF Fitzgerald RF Nachreiner JB Kaneene WE Braselton CL Chiapuzio 1999 Use of pamidronate to reverse vitamin D3-induced toxicosis in dogs Am J Vet Res 60 1092 1097
50. I Sanchez-Perez R Perona 1999 Lack of c-Jun activity increases survival to cisplatin FEBS Lett 453 151 158
51. PA Schenck DJ Chew 2005 Prediction of serum ionized calcium concentration by use of serum total calcium concentration in dogs Am J Vet Res 66 1330 1336
52. GG Schwartz MH Wang M Zang RK Singh GP Siegal 1997 1 alpha,25- Dihydroxyvitamin D (calcitriol) inhibits the invasiveness of human prostate cancer cells Cancer Epidemiol Biomarkers Prev 6 727 732
53. DC Smith CS Johnson CC Freeman J Muindi JW Wilson DL Trump 1999 A phase I trial of calcitriol (1,25-dihydroxycholecalciferol) in patients with advanced malignancy Clin Cancer Res 5 1339 1345
54. R St Arnaud A Arabian R Travers F Barletta M Raval-Pandya K Chapin J Depovere C Mathieu S Christakos MB Demay FH Glorieux 2000 Deficient mineralization of intramembranous bone in vitamin D-24-hydroxylase-ablated mice is due to elevated 1,25-dihydroxyvitamin D and not to the absence of 24,25-dihydroxyvitamin D Endocrinology 141 2658 2666
55. T Taguchi A Nazneen MR Abid MS Razzaque 2005 Cisplatin-associated nephrotoxicity and pathological events Contrib Nephrol 148 107 121
56. W Tang VA Ziboh RR Isseroff D Martinez 1987 Novel regulatory actions of 1 alpha,25-dihydroxyvitamin D3 on the metabolism of polyphosphoinositides in murine epidermal keratinocytes J Cell Physiol 132 131 136
57. DL Trump J Muindi M Fakih WD Yu CS Johnson 2006 Vitamin D compounds: clinical development as cancer therapy and prevention agents Anticancer Res 26 2551 2556
58. C Widmann P Gerwins NL Johnson MB Jarpe GL Johnson 1998 MEK kinase 1, a substrate for DEVD-directed caspases, is involved in genotoxin-induced apoptosis Mol Cell Biol 18 2416 2429
59. SJ Withrow JM Liptak RC Straw WS Dernell VJ Jameson BE Powers JL Johnson JH Brekke EB Douple 2004 Biodegradable cisplatin polymer in limb-sparing surgery for canine osteosarcoma Ann Surg Oncol 11 705 713
60. LG Wolfe BB Smith MA Toivio-Kinnucan EA Sartin RP Kwapien RA Henderson S Barnes 1986 Biologic properties of cell lines derived from canine mammary carcinomas J Natl Cancer Inst 77 783 792
61. WD Yu MC McElwain RA Modzelewski DM Russell DC Smith DL Trump CS Johnson 1998 Enhancement of 1,25-dihydroxyvitamin D3-mediated antitumor activity with dexamethasone J Natl Cancer Inst 90 134 141